- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (70)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (720)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (156)
- Colon Cancer (164)
- Colorectal Cancer (112)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (8)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (8)
- Kidney Cancer (126)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (286)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (172)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (96)
- Tonsil Cancer (30)
- Uterine Cancer (80)
- Vaginal Cancer (16)
- Vulvar Cancer (20)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (632)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (910)
- Research (396)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (608)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (322)
- Symptoms (184)
- Treatment (1786)
Antifibrotic agent showing benefits for advanced myelofibrosis
BY Ron Gilmore
2 minute read | Published January 14, 2015
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on January 14, 2015
A study investigating the potential of the antifibrotic compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.
The study, led by Srdan Verstovsek, M.D., Ph.D., professor of Leukemia at MD Anderson Cancer Center, showed the compound was well tolerated in observing 27 patients. Verstovsek’s research results were presented in December at the 56th Annual Meeting of the American Society of Hematology (ASH) annual conference in San Francisco, and were published in the ASH journal Blood.
“There was no evidence of drug-related myelosuppression or suppression of the bone marrow’s ability to produce blood cells and platelets. We also saw encouraging trends in both clinical and histologic aspects of the disease,” said Verstovsek. “With demonstrated reduction in bone marrow fibrosis, stable to improved hematologic parameters, symptom responses and stable to reduced spleen size, it is clear that there is merit for further development of PRM.”
Myelofibrosis is caused by the accumulation of malignant bone marrow cells that triggers an inflammatory response, scarring the bone marrow and limiting its ability to produce blood, resulting in anemia. About 3,000 new cases of myelofibrosis are diagnosed in the United States each year. Average survival ranges from two to 11 years, depending on a variety of factors.
Patients with myelofibrosis experience many debilitating symptoms, including fatigue, weight loss, abdominal pain, severe itching, night sweats and bone pain. A swollen spleen is one hallmark of the disease tied to many of its symptoms.
PRM is a recombinant form of Pentraxin-2, a human protein that acts at sites of tissue damage, inducing macrophage differentiation to prevent and reverse fibrosis. PRM has demonstrated broad antifibrotic activity in multiple preclinical models of established fibrotic diseases and no dose-limiting toxicities in phase I trials. Verstovsek found that PRM was well tolerated both in combination with and without ruxolitinib, another potent myelofibrosis therapy.
Topics
Clinical Trials